Optimal therapy and management of endometrial cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 1, 2003, Pages 37-47

  Sonoda, Yukio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial adenocarcinoma; Endometrial cancer; Uterine cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL; PACLITAXEL; PLATINUM DERIVATIVE; PROGESTERONE; TAMOXIFEN;

CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; ENDOMETRIUM CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; LAPAROSCOPIC SURGERY; NEUROPATHY; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT PLANNING; UTERUS;

EID: 0037320655     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.1.37     Document Type: Review

References (78)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52, 23-47 (2002).
2. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Blaustein's Pathology of the Female Genital Tract (4th Edition) Kurman RJ (Ed.). Springer-Verlag. New York, NY, USA, 439-486 (1994).
3. Platz CE, Benda JA. Female genital tract cancer. Cancer 75(1 Suppl.), 270-294 (1995).
4. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet. Gynecol. 64(3), 417-420 (1984).
5. Whitaker GK, Lee RB, Benson WL. Carcinoma of the endometrium in young women. Mil. Med. 151(1), 25-31 (1986).
6. Hill HA, Coates RJ, Austin H et al. Racial differences in tumor grade among women with endometrial cancer. Gynecol. Oncol. 56(2), 154-163 (1995).
7. Connell PP, Rotmensch J, Waggoner SE, Mundt AJ. Race and clinical outcome in endometrial carcinoma. Obstet. Gynecol. 94(5 Pt 1), 713-720 (1999).
8. Barakat RR, Grigsby PW, Sabbatini P, Zaino RJ. Corpus: epithelial tumors. In: Principles and Practice of Gynecologic Oncology (3rd Edition). Hoskins WJ, Perez CA, Young RC (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA 924 (2000).
9. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving anti-estrogens. Cancer Treat. Rep. 69(2), 237-238 (1987).
10. Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1(8630), 117-120 (1989).
11. Fisher B, Costantino, JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
12. Vasen HF, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110(4), 1020-1027 (1996).
13. Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int. J. Cancer 81(2), 214-218 (1999).
14. Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum. Mol. Genet. 6(1), 105-110 (1997).
15. Hawwa ZM, Nahhas WA, Copenhaver EH. Postmenopausal bleeding. Lahey Clin. Found Bull. 19(2), 61-70 (1970).
16. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89(8), 1765-1772 (2000).
17. Karlsson B, Granberg S, Wikland M et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding - a Nordic multicenter study. Am. J. Obstet. Gynecol. 172(5), 1488-1494 (1995).
18. Goldstein RB, Bree RL, Benson CB et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J. Ultrasound Med. 20(10), 1025-1036 (2001).
19. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet. Gynecol. 81(5), 660-664 (1993).
20. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol. Oncol. 66(2), 233-237 (1997).
21. Kedar RP, Bourne TH, Powles TJ et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 28, 343(8909), 1318-1321 (1994).
22. Cohen I, Rosen DJ, Shapira J et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol. Oncol. 52(2), 185-190 (1994).
23. Ascher SM, Imaoka I, Lage JM. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 214(1), 29-38 (2000).
24. Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology 197(3), 603-608 (1995).
25. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet.Gynecol. 90(3), 441-447 (1997).
26. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60 (8 Suppl.), 2035-2041 (1987).
27. Hatch K. Endometrial cancer: what is the proper extent of surgical staging? Proc. 25th Ann. Conf. Soc. Gynecol. Oncol. (1994).
28. Vorgias G, Hintipas E, Katsoulis M, Kalinoglou N, Dertimas B, Akrivos T. Intraoperative gross examination of myometrial invasion and cervical infiltration in patients with endometrial cancer: decision-making accuracy. Gynecol. Oncol. 85(3), 483-486 (2002).
29. Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J. Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet. Gynecol. 95(4), 553-556 (2000).
30. Eltabbakh GH. Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer. Am. J. Obstet. Gynecol. 184(6), 1177-1181 (2001).
31. Girardi F, Petru E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol. Oncol. 49(2), 177-180 (1993).
32. Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 56(1), 29-33 (1995).
33. Yabushita H, Shimazu M, Yamada H et al. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol. Oncol. 80(2), 139-144 (2001).
34. Cirisano FD Jr, Robboy SJ, Dodge RK et al. The outcome of Stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol. Oncol. 77(1), 55-65 (2000).
35. Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol. Oncol 74(3), 465-467 (1999).
36. Partridge EE, Jessup JM, Donaldson ES et al. 1996 Patient Care Evaluation Study (PCE) of cancer of the corpus uteri. National Cancer Database (NCDB), American College of Surgery. Gynecol. Oncol. 72(3), 445 (1999).
37. Society of Gynecologic Oncologists. Referral Guidelines in Gynecologic Oncology. Gynecol. Oncol. 78, S1-13 (2000).
38. Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD, Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet. Gynecol. 97(5 Pt 1), 707-711 (2001).
39. Childers JM, Brzechffa PR, Hatch KD, Surwit EA. Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol. Oncol. 51(1), 33-38 (1993).
40. Gemignani ML, Curtin JP, Zelmanovich J, Patel DA, Venkatraman E, Barakat RR. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol. Oncol. 73(1), 5-11 (1999).
41. Spirtos NM, Schlaerth JB, Gross GM, Spirtos TW, Schlaerth AC, Ballon SC. Cost and quality-of-life analyses of surgery for early endometrial cancer: laparotomy versus laparoscopy. Am. J. Obstet. Gynecol. 174(6), 1795-1799, discussion 1799-1800 (1996).
42. Eltabbakh GH, Shamonki MI, Moody JM, Garafano LL. Laparoscopy as the primary modality for the treatment of women with endometrial carcinoma. Cancer 91(2), 378-387 (2001).
43. Boike G, Lurain J, Burke J. A comparison of laparoscopic management of endometrial cancer with traditional laparotomy. Gynecol. Oncol. 52, 105 (1994).
44. Straughn JM Jr, Huh WK, Kelly FJ et al. Conservative management of Stage I endometrial carcinoma after surgical staging. Gynecol. Oncol. 84(2), 194-200 (2002).
45. Roberts JA, Brunetto VL, Keys HM et al. A Phase III randomized study of surgery vs. surgery plus adjuvant radiation therapy in intermediate risk endometrial carcinoma (GOG 99). Proc. Soc. Gynecol. Oncol. Ann. Meet. 70 (1998).
46. Fanning J. Treatment for early endometrial cancer. Cost-effectiveness analysis. J. Reprod. Med. 44(8), 719-723 (1999).
47. Barnes MN, Roland PY, Straughn M, Kilgore LC, Alvarez RD, Partridge EE. A comparison of treatment strategies for endometrial adenocarcinoma: analysis of financial impact. Gynecol. Oncol. 74(3), 443-447 (1999).
48. Gretz HF 3rd, Economos K, Husain A et al. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with Stage I endometrial carcinoma. Gynecol. Oncol. 61(3), 409-415 (1996).
49. Naumann RW, Higgins RV, Hall JB. The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists. Gynecol. Oncol 75(1), 4-9 (1999).
50. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in Stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet. Gynecol. 56(4), 419-427 (1980).
51. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with Stage-I endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 22, 355(9213), 1404-1411 (2000).
52. Preyer O, Obermair A, Formann E et al. The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with Stage IIIA uterine cancer. Gynecol. Oncol. 86(3), 269-273 (2002).
53. Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol. Oncol. 46(2), 145-149 (1992).
54. Hirai Y, Takeshima N, Kato T, Hasumi K Malignant potential of positive peritoneal cytology in endometrial cancer. Obstet. Gynecol. 97(5 Pt 1), 725-728 (2001).
55. Piver MS, Recio FO, Baker TR, Hempling RE. A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma. Gynecol. Oncol. 47, 373-376 (1992).
56. Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 64(5), 1011-1016 (1989).
57. Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgical-pathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 40(1), 55-65 (1991).
58. Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical Stage IV endometrial carcinoma; a study of 47 cases. Gynecol. Oncol. 52(2), 237-240 (1994).
59. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol. Ontcol. 78(2), 85-91 (2000)
60. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol. Oncol. 67(1), 56-60 (1997).
61. Smith RS, Kapp DS, Chen Q, Teng NN. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int. J. Radiat. Oncol. Biol Phys. 48(3), 767-778 (2000).
62. Kupelian PA, Eifel PJ, Tornos C, Burke TW, Delclos L, Oswald MJ. Treatment of endometrial carcinoma with radiation therapy alone. Int. J. Radiat. Oncol. Biol. Phys. 27(4), 817-824 (1993).
63. Rose PG, Baker S, Kern M et al. Primary radiation therapy for endometrial carcinoma: a case controlled study. Int. J. Radiat. Oncol. Biol. Phys. 27(3), 585-590 (1993).
64. Randall TC, Karman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet. Gynecol. 90(3), 434-440 (1997).
65. Kaku T, Yoshikawa H, Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 167(1), 39-48 (2001).
66. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol. Oncol. 17(1), 85-103 (1984).
67. Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR. Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients. Int. J. Radiat. Oncol. Biol. Phys. 17(1), 29-34 (1989).
68. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol. Oncol. 60(2), 288-291 (1996).
69. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol. Oncol. 75(1), 99-102 (1999).
70. Gemignani ML, Alektiar KM, Leitao M et al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int. J. Radiat. Oncol. Biol. Phys. 50(3), 687-694 (2001).
71. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 17(6), 1736-1744 (1999).
72. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 19(2), 364-367 (2001).
73. Pandya KJ, Yeap BY, Weiner LM et al. Megestrol and tamoxifen in patients with advanced endometrial cancer an Eastern Co-operative Oncology Group study (E4882). Am. J. Clin. Oncol. 24(1), 43-46 (2001).
74. Fiorica J, Brunetto V, Hanjani P, Lentz S, Mannel R, Anderson W. A Phase II study (GOG 153) of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate and tamoxifen citrate. Proc. Am. Soc. Clin. Oncol. 19, 379a (2000).
75. Thigpen T, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc. Am. Soc. Clin. Oncol. 12, 261 (1993).
76. Fleming G, Brunetto V, Bentley R et al. Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus paclitaxel (TAX) plus granulocyte colony-stimulating factor (G-CSF) in patients with advanced or recurrent endometrial cancer: a report on Gynecologic Oncology Group (GOG) protocol. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 1498).
77. Dimopoulos MA, Papadimitriou CA, Georgoulias V et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a Phase II multicenter study. Gynecol. Oncol. 78(1), 52-57 (2000).
78. Fleming GF, Brunetto VI, Mundt AJ, Burks RT, Look KY, Reid G. Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paditaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 807).